JAMA

Asep Medical's Sepsis Diagnostic Technology Can Provide Improved Odds for Pediatric Appendicitis

Retrieved on: 
Tuesday, February 27, 2024
Asep, Incidence, Sepsis, UBC, Medical director, American Medical Association, JAMA, Abdominal pain, Biomarker, Gene expression, Appendectomy, Patent, Appendicitis, Patient, Journal, Data analysis, Pediatrics, Diagnosis, Mortality, Gene expression profiling, Vaccine

VANCOUVER, BC, Feb. 27, 2024 /PRNewswire/ - Asep Medical Holdings Inc. ("Asep Inc." or the "Company") (CSE: ASEP) (OTCQB: SEPSF) (FSE: JJ8) is pleased to announce that its proprietary gene expression signature for sepsis can provide an improved assessment of the severity of appendicitis in children.

Key Points: 
  • VANCOUVER, BC, Feb. 27, 2024 /PRNewswire/ - Asep Medical Holdings Inc. ("Asep Inc." or the "Company") (CSE: ASEP) (OTCQB: SEPSF) (FSE: JJ8) is pleased to announce that its proprietary gene expression signature for sepsis can provide an improved assessment of the severity of appendicitis in children.
  • The study found that the "diagnostic study of 71 patients with pediatric appendicitis using systems immunology methods revealed a mechanistic understanding of severe disease, indicating immune dysregulation similar to that observed in sepsis.
  • The study concluded that early diagnostics and management strategies for pediatric PA should be informed by underlying immune dysregulation and similarities to sepsis.
  • Based on the new potential benefits of this ER technology, we look forward to improving outcomes for children presenting with abdominal pain in the ER."

Spectral AI Appoints Dr. J. Michael DiMaio to Board of Directors

Retrieved on: 
Monday, February 12, 2024
Hospital, American Heart Association, Artificial intelligence, Society, University, American College, Health, American Surgical Association, Cardiothoracic surgery, Bangladesh Technical Education Board, Register, NIH, Duke University Hospital, JAMA, Physician, MDAI, International Society, General surgery, Abstract, Internal medicine, United, Society of Thoracic Surgeons, Research, Human services, Spectral, FDA, American College of Surgeons, National Science Foundation, American Burn Association, Lung transplantation, Publication, Medical device

DALLAS, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on the unmet need for improved medical diagnostics to allow faster and more accurate treatment decisions in wound care, today announces the appointment of Dr. J. Michael DiMaio to its Board of Directors, effective February 7, 2024.

Key Points: 
  • DALLAS, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on the unmet need for improved medical diagnostics to allow faster and more accurate treatment decisions in wound care, today announces the appointment of Dr. J. Michael DiMaio to its Board of Directors, effective February 7, 2024.
  • Dr. DiMaio joins the Board as a non-executive member to fill the vacancy left by the departure of Mr. Michael Murphy.
  • Dr. Michael DiMaio is one of the Company’s founders and previously served as the Company’s Chief Executive Officer and Chairman of the Board of Directors from 2011 to 2020.
  • "I am pleased to welcome back Dr. Michael DiMaio to Spectral AI’s Board of Directors," said Richard Cotton, Chairman of the Board of Directors.

BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarney to the Board of Directors

Retrieved on: 
Thursday, February 8, 2024
Society, International Society, Health, Naltrexone, Knowledge, American Journal, DSM-IV codes, Substance abuse, Opioid use disorder, American College, Addiction medicine, CFO, Addiction, Therapy, GSK plc, American Medical Association, Corcept Therapeutics, OTCQB, Principal investigator, Alzheimer's disease, Neuroscience, Parkinson's disease, Doctor of Philosophy, Merck, Journal, OUD, NACDA, Research, JAMA, Obesity, Anxiety, American Psychiatric Association, Pharmaceutical industry

ANAHEIM, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, announced that its subsidiary BioCorRx Pharmaceuticals Inc., has appointed Kate Beebe DeVarney, Ph.D. to its Board of Directors.

Key Points: 
  • ANAHEIM, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, announced that its subsidiary BioCorRx Pharmaceuticals Inc., has appointed Kate Beebe DeVarney, Ph.D. to its Board of Directors.
  • Dr. DeVarney is the President, Chief Operating Officer, and a Director of Titan Pharmaceuticals, Inc.  She was previously Titan’s Chief Scientific Officer and has been with the company since 2007.
  • Lourdes Felix, CEO, CFO, and Director of BioCorRx Inc., commented, “We are honored and excited to welcome Dr. DeVarney to the BioCorRx Pharmaceuticals board.
  • I look forward to working closely with the management team to bring BICX104 to market.”

Alberta’s new policies are not only anti-trans, they are anti-evidence

Retrieved on: 
Monday, February 5, 2024
Policy, JAMA, Parent, Knowledge, Curriculum, Family, Suicidal ideation, Legislation, Research, Fear, Government, Egale Canada, Child, Patient, Athlete, American Medical Association, Fearmongering, Human, School, Scientific American, United Conservative Party, Facial muscles, Name, Mental health, Testosterone, Ethics, HRT, Journal, Smith, Risk, Education, Violence, Sport, Health, Suicide, Puberty, Muscle memory, Woman

Like other experts, we worried these policies would mimic the parental rights legislation recently introduced in Saskatchewan and New Brunswick.

Key Points: 
  • Like other experts, we worried these policies would mimic the parental rights legislation recently introduced in Saskatchewan and New Brunswick.
  • Smith has unveiled a suite of policies that directly attack trans and gender-diverse children and youth in Alberta.
  • As we explain below, these policies are at odds with research about gender-affirming care, curriculum and sports.

Evidence on trans-affirming care

  • Like all medicines, side effects are a risk but researchers caution against fear-mongering in response to gender-affirming care.
  • The evidence about trans-affirming health care for youth is clear — it saves lives.
  • Rather than restrict life-saving medical care, experts in fertility medicine call for increased accessibility for trans people to fertility services.

Sex education evidence

  • Classroom instruction on gender, sexuality and sexual orientation also now requires parental notification and opt-in.
  • Finally, third-party resource materials on gender, sexuality and sexual orientation in schools need to be pre-approved by the ministry to make sure they’re “age-appropriate.” Education experts agree that what is needed to protect youth — including cisgender and heterosexual kids — from potential abuse is robust and consent-based sexual health education.
  • Youth have the right to knowledge and skills about their bodies, consent, safe/unsafe touch and healthy relationships.

Risk of parental, peer rejection

  • This process essentially requires schools to “out” youth to their parents, who may reject their children.
  • Smith incorrectly suggests that parental rejection of 2SLGBTQIA+ kids is rare.
  • For those who experience family rejection, the rates of suicide are incredibly high.

Trans athletes evidence

  • Smith’s policy will also ban trans girls and women athletes from participating in competitive women’s sports.
  • Some scientists maintain that trans women and girls have no “biological advantage” over cisgender girls and women.
  • A book on the topic that reviewed evidence on testosterone determined there is no direct relation between the hormone and athletic performance.

What’s the truth?

  • In contrast, trans youth who are affirmed in schools, health care and in sports have better self-confidence and relationships with their parents.
  • Smith has incorrectly warned there are risks associated with affirmation and inclusion in schools for trans kids.
  • It includes more information on clinical guidelines for the prescription of puberty blockers for the purposes of gender-affirming care.


Corinne L. Mason receives funding from SSHRC. Leah Hamilton receives funding from SSHRC.

Junshi Biosciences Announces Toripalimab’s NDA Accepted by the Singapore Health Sciences Authority

Retrieved on: 
Friday, February 2, 2024
Orbis, HC, JAMA, TGA, HSA, European, Shirin David, Immunotherapy, Trial of the century, Nasopharyngeal carcinoma, NPC, PFS, Clutch (eggs), Cisplatin, Patient, Safety, ASCO, New Drug Application, American Medical Association, Shanda, Progression-free survival, FDA, Marketing, OCE, Dor, Food, Society, Health Canada, Risk, Journal, Death, Health care, NDA, HKEX, Pharmaceutical industry

This NDA was submitted through Project Orbis, an initiative of the US Food and Drug Administration (FDA)’s Oncology Center of Excellence (OCE).

Key Points: 
  • This NDA was submitted through Project Orbis, an initiative of the US Food and Drug Administration (FDA)’s Oncology Center of Excellence (OCE).
  • At present, eight regulatory agencies have joined Project Orbis, including the FDA, the Australia Therapeutic Goods Administration (“TGA”), HSA, Health Canada (HC), the U.K.
  • Previously, two NDAs for toripalimab for the treatment of NPC had been submitted to the TGA through Project Orbis and were successfully accepted.
  • Junshi Biosciences will explore accelerated marketing opportunities in countries and regions where it is applicable.

Pair Team Announces the Appointment of Nate Favini, M.D., M.S., as Inaugural Chief Medical Officer

Retrieved on: 
Thursday, February 1, 2024
Health, SAN, JAMA, Population health, Growth, Senior, Nate, CareMore, Federally Qualified Health Center, Patient, Safety, UCLA, American Medical Association, Public health, Harvard Medical School, Forward, Social support, Journal, Connie, American Journal, Management

SAN FRANCISCO, Feb. 1, 2024 /PRNewswire/ -- Pair Team, a virtual and community-based care solution connecting Medicaid's highest-risk patients to high-quality care, today announced the appointment of its first-ever Chief Medical Officer, Nate Favini, M.D., M.S. In this role, Nate will oversee clinical services at Pair Team, including supporting and scaling its clinical teams, leading population health efforts, shaping the company's value-based care strategy and developing new clinical programs and services to improve the health of its patients and lower total costs of care.

Key Points: 
  • We're poised for another year of explosive growth and hiring Nate enables us to do so," said Neil Batlivala, co-founder and CEO of Pair Team.
  • Nate joins Pair Team from Forward, where he served as Chief Medical Officer.
  • In addition to Nate's new role as Chief Medical Officer, Pair Team has also announced two new appointments within its leadership team:
    Connie Kim , Executive Vice President of Operations.
  • For more information about Pair Team or if you're interested in joining its team, please visit www.pairteam.com .

CDC Foundation's Live to the Beat campaign spotlights cardiovascular disease in Black women, issuing a call-to-action to help Black women prioritize self-care for their own heart health

Retrieved on: 
Thursday, February 1, 2024
Steps, Anxiety, CVD, JAMA, Research, Health equity, Cardiovascular disease, News, House, American Medical Association, Moyamoya disease, Friends, Beat, American Heart Month, CDC, Depression, Social media, Health education, Challenge, Risk, Journal, Cancer, EST, Stroke, Health, White, Woman

Black women are bearing the brunt of the toll cardiovascular disease (CVD) is having on women in the United States.

Key Points: 
  • Black women are bearing the brunt of the toll cardiovascular disease (CVD) is having on women in the United States.
  • CDC Foundation's Live to the Beat campaign is launching a "Heart2Heart Challenge" to encourage Black women to give themselves permission to prioritize self-care for their own heart health.
  • "Black women are the figurative heartbeats of Black families and communities, but many of their own hearts are in trouble.
  • Now entering its third year, the CDC Foundation's Live to the Beat campaign is CDC's first national cardiovascular disease prevention campaign developed for the Black community.

Waystar Partners with MEDITECH to Accelerate Mission of Simplifying Healthcare Payments

Retrieved on: 
Thursday, February 1, 2024
Partnership, Expanse, EHR, JAMA, Patient, Friction, American Medical Association, MEDITECH, Journal, Organization, Health, Sales

LEHI, Utah and LOUISVILLE, Ky., Feb. 1, 2024 /PRNewswire/ -- Waystar Technologies, Inc., a provider of leading healthcare payment technology, today announced a new partnership with MEDITECH, a leading global electronic health record (EHR) provider. Through the partnership, healthcare organizations currently working with MEDITECH will have the ability to leverage Waystar's award-winning platform, empowering those providers to remove friction from their financial operations and focus on delivering high-quality care to patients.

Key Points: 
  • As administrative expenses increasingly weigh on the U.S. healthcare system, partnerships like Waystar and MEDITECH are essential to reducing the burden on providers and patients.
  • Matt Hawkins, Chief Executive Officer of Waystar, said, "Waystar and MEDITECH share a commitment to transforming the healthcare landscape through digital innovation.
  • This partnership immediately expands the reach of our platform, furthering our mission of simplifying healthcare payments.
  • "MEDITECH is pleased to welcome Waystar into our Alliance program to provide clients with another integrated solution," said MEDITECH Chief Business Development Officer Jim Merlin.

ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2024

Retrieved on: 
Wednesday, January 24, 2024
DAN, Woman, ResMed, Patient, Wind, Software as a service, Magnet, American Medical Association, COPD, JAMA, Investment, CDI, Journal, Acquisition, Chronic obstructive pulmonary disease, Webcast, Retirement, Australian Securities Exchange, CHESS, Mask, Growth

SAN DIEGO, Jan. 24, 2024 (GLOBE NEWSWIRE) -- ResMed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended December 31, 2023.

Key Points: 
  • Gross margin decreased by 50 basis points mainly due to costs associated with a field safety notification for masks with magnets.
  • SG&A expenses improved to 19.1 percent of revenue in the quarter, compared with 20.5 percent in the same period of the prior year.
  • ResMed has received a waiver from the ASX’s settlement operating rules, which will allow ResMed to defer processing conversions between its common stock and CDI registers from February 7, 2024, through February 8, 2024, inclusive.
  • ResMed will discuss its second quarter fiscal year 2024 results on its webcast at 1:30 p.m. U.S. Pacific Time today.

Junshi Biosciences Announces JAMA Publication of Results from NEOTORCH, a Randomized Phase 3 Trial of Perioperative Toripalimab plus Chemotherapy for Patients with Resectable Non-Small Cell Lung Cancer

Retrieved on: 
Thursday, January 18, 2024
Patient, EFS, ASCO, Diagnosis, Trial of the century, Society, American Medical Association, Lung cancer, NSCLC, Shanghai Chest Hospital, JAMA, Journal, Safety, Shanghai Jiao Tong University, Medical device

NEOTORCH is a randomized, double-blind, placebo-controlled phase 3 trial evaluating the efficacy and safety of toripalimab in combination with perioperative platinum-based chemotherapy vs chemotherapy alone in patients with resectable stage II or III NSCLC.

Key Points: 
  • NEOTORCH is a randomized, double-blind, placebo-controlled phase 3 trial evaluating the efficacy and safety of toripalimab in combination with perioperative platinum-based chemotherapy vs chemotherapy alone in patients with resectable stage II or III NSCLC.
  • NEOTORCH is the world’s first phase III clinical study of a anti-PD-1 monoclonal antibody for NSCLC perioperative treatment (including neoadjuvant and adjuvant) with positive EFS results.
  • As a phase 3 clinical study of perioperative treatment, NEOTORCH enrolled the largest sample of resectable stage III NSCLC patients in China.
  • We anticipate that toripalimab will guide China’s perioperative lung cancer treatment into a new era.